Bright Minds Biosciences Inc. (DRUG)

1.0772 +0.0572 (+5.61%) 收市：04:00PM EDT

Bright Minds Biosciences Inc.

19 Vestry Street
New York, NY 10013
United States

https://brightmindsbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Ian McDonald	Co-Founder, CEO, President & Director	無	無	1989
Mr. Ryan E. S. K. Cheung B.Com., CA, CPA	Chief Financial Officer	87.86k	無	1978
Dr. Jan Torleif Pedersen M.Sc., Ph.D.	Chief Science Officer & Director	178.31k	無	1965
Dr. Mark A. Smith M.D., Ph.D.	Chief Medical Officer	239.8k	無	1955
Dr. Emer Leahy M.B.A., Ph.D.	Consultant	無	無	1967

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

公司管治

截至 無 止，Bright Minds Biosciences Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。